Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 24,19€ (+0,25%). La mediana è 23,61€ (−2,15%).
| Acquista |
15 |
| Mantieni |
23 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Pfizer's dividend supported now but cash demands pose rising risk
Pfizer yields about 6.1% but its dividend payout exceeds 200% of earnings; measured against free cash flow the cash dividend payout ratio is roughly 90%. The company holds about $1 billion in cash and $10.7 billion in short-term investments and pays roughly $2.5 billion in dividends each quarter, so the payout is covered today. Main near-term risks are patent expirations and higher R&D needs that will compete with the same cash pool supporting the dividend. » Altro su finance.yahoo.com
Pfizer yields 6% as stock trades at discount amid debt and patent headwinds
Pfizer's shares have tumbled about 38% over five years as COVID-19 revenues collapsed and key drugs face patent cliffs, while acquisitions such as Seagen and Metsera pushed net debt above $53 billion. Despite these challenges, Pfizer generated nearly $11 billion in free cash flow over the last twelve months and saw 21% revenue growth from Seagen's cancer portfolio. The stock's 6% dividend yield reflects the discount, and the payout could remain sustainable if Pfizer reduces debt and grows through acquisitions and its pipeline. » Altro su finance.yahoo.com
Pfizer posts modest operational growth as new drugs and cost cuts drive recovery
Pfizer reported 1% operational revenue growth in Q2 2026 to $15.0 billion, with revenue excluding Comirnaty and Paxlovid up 5% and launched/acquired products generating $3.2 billion (up 18% operationally). Padcev and the Vyndaqel family posted strong gains, while management raised the midpoint of full-year guidance and expects about $5.7 billion in net savings by end-2026. The company remains exposed to looming patent expirations on drugs such as Eliquis, Ibrance and Xtandi, with an estimated $1.1 billion unfavorable revenue impact in 2026 from generics and biosimilars, leaving uncertainty whether new products can fully offset lost franchise revenue. » Altro su finance.yahoo.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 13,20Mld | 5,67% |
| Utile lordo | 9,61Mld | 19,63% |
| Utile netto | −216,05M | 108,71% |
| EBITDA | 1,05Mld | 76,80% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 139,82Mld€ |
Numero di azioni | 5,70Mld |
Massimo/minimo a 52 settimane | 24,69€ - 20,25€ |
Rendimento da dividendo | 6,09% |
Dividendi TTM | 1,48€ |
Prossimo dividendo | 0,37€ |
Beta | 0,28 |
Rapporto P/E | 37,75 |
Rapporto PEG | −0,63 |
Rapporto P/B | 1,91 |
Rapporto P/S | 2,56 |
Profilo aziendale
Pfizer Inc. erforscht, entwickelt, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Medikamente und Impfstoffe in verschiedenen therapeutischen Bereichen an, darunter Herz-Kreislauf-Stoffwechsel- und Frauengesundheit unter den Marken Premarin und Eliquis; Biologika, kleine Moleküle, Immuntherapien und Biosimilars unter den Marken Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena und Braftovi; und sterile injizierbare und antiinfektiöse Arzneimittel sowie orale COVID-19-Behandlung unter den Marken Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga und Paxlovid. Das Unternehmen bietet auch Arzneimittel und Impfstoffe in verschiedenen therapeutischen Bereichen an, wie Pneumokokken, Meningokokken, Zeckenenzephalitis und COVID-19 unter den Marken Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba und der Prevnar-Familie; Biosimilars für chronische Immun- und Entzündungskrankheiten unter den Marken Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis und Cibinqo sowie Amyloidose, Hämophilie und endokrine Erkrankungen unter den Marken Vyndaqel/Vyndamax, BeneFIX und Genotropin. Darüber hinaus ist das Unternehmen im Bereich der Auftragsherstellung tätig. Das Unternehmen beliefert Großhändler, Einzelhändler, Krankenhäuser, Kliniken, Behörden, Apotheken und einzelne Anbieter sowie Zentren für Krankheitskontrolle und Prävention. Das Unternehmen hat Kooperationsvereinbarungen mit Bristol-Myers Squibb Company, Astellas Pharma US, Inc, Myovant Sciences Ltd, Akcea Therapeutics, Inc, Merck KGaA, Valneva SE, BioNTech SE und Arvinas, Inc. Pfizer Inc. wurde 1849 gegründet und hat seinen Hauptsitz in New York, New York.
| Nome | Pfizer |
| CEO | Albert Bourla |
| Sede centrale | New York City,
ny Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Prodotti farmaceutici |
| Quotazione in borsa | 26/02/2021 |
| Dipendenti | 75.000 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | PFE |
XETRA | PFE.DE |
XETRA | PFE.F |
Frankfurt | PFE.F |
Düsseldorf | PFE.DU |
Hamburg | PFE.HM |
Milan | 1PFE.MI |
London | 0Q1N.L |
SIX | PFE.SW |
München | PFE.MU |
Wien | PFE.VI |
Scopri gli asset
Gli azionisti di Pfizer investono anche nei seguenti asset
